Printer Friendly

Empagliflozin first antidiabetes drug to gain cardioprotective indication.

Empagliflozin is the first antidiabetes medication to be approved for reducing the risk of cardiovascular death in patients with type 2 diabetes and concomitant cardiovascular disease.

The Food and Drug Administration granted the new indication based on the EMPA-REG OUTCOME study a postmarketing analysis that found that empagliflozin (Jardiance, Boehringer-Ingelheim) reduced the risk of cardiovascular death by 38% when added to standard-of-care type 2 diabetes therapy.

"This new indication represents a tremendous step forward in our efforts to reduce the impact of cardiovascular disease among adults with type 2 diabetes and established cardiovascular disease," Paul Fontayne, president and CEO of Boehringer-Ingelheim, said in a press statement. "We believe that this medicine is an important new treatment option for this patient population."

When empagliflozin was approved for type 2 diabetes in 2014, the FDA required an additional postmarketing study to examine its cardiovascular safety. The 48-month, open-label EMPA-REG enrolled more than 7,000 patients who had type 2 diabetes and a high risk of cardiovascular disease.

The study's big surprise, however, was not empagliflozin's safety, but its striking cardioprotective qualities. It reduced by 14% the risk of the primary endpoint, a composite of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction (N Engl J Med. 2015;373:2117-28).

When examined as individual outcomes in a secondary analysis, empagliflozin significantly reduced the risk of cardiovascular death by 38%. However, risk reductions on the other endpoints were not significant. Nevertheless, experts called empagliflozin's cardiovascular benefit a potential game-changer for the clinical challenge of managing patients with both disorders.

But the drug barely squeaked by its June FDA approval hearing for the cardioprotective indication, receiving a split 12-11 endorsement from the Endocrinologic and Metabolic Drugs Advisory Committee. The major sticking point was that EMPA-REG was a test of empagliflozin's cardiovascular safety, not its efficacy, and that cardiovascular death was not a prespecified endpoint.

Although there were no significant cardiovascular safety issues, empagliflozin has been associated with hypotension, serious urinary tract infection, acute kidney injury, and genital infections.

"Cardiovascular disease is a leading cause of death in adults with type 2 diabetes mellitus," Jean-Marc Guettier, MD, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, wrote in a press statement.

'Availability of antidiabetes therapies that can help people live longer by reducing the risk of cardiovascular death is an important advance for adults with type 2 diabetes."


COPYRIGHT 2016 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Sullivan, Michele G.
Publication:Family Practice News
Date:Dec 1, 2016
Previous Article:What's next? Trump administration may focus on reforming ACA, tort law.
Next Article:Antiamyloid solanezumab fails to slow decline in mild AD.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters